Survivin gene expression in early-stage non-small cell lung cancer

Monica Falleni, Caterina Pellegrini, Antonio Marchetti, Barbara Oprandi, Fiamma Buttitta, Fabio Barassi, Luigi Santambrogio, Guido Coggi, Silvano Bosari

Research output: Contribution to journalArticle

150 Citations (Scopus)

Abstract

Survivin is an inhibitor of apoptosis protein, overexpressed in most human malignancies and implicated in mitosis regulation and preservation of cell viability. In order to investigate the prevalence and clinical significance of survivin in early-stage non-small cell lung carcinoma (NSCLC), survivin mRNA levels and protein expression were evaluated, using quantitative real-time RT-PCR and immunohistochemistry, respectively, in a series of 83 patients with stage I (IA and IB) surgically resected NSCLC. Detectable survivin mRNA levels could be demonstrated in all non-neoplastic lung tissue samples and in the tumours analysed. Survivin mRNA levels were elevated in 80 carcinomas (96%) compared to normal lung (p = 0.008). Among all tumours, survivin transcripts were present at a higher level in squamous cell carcinomas (p = 0.0022). Cytoplasmic and nuclear immunoreactivity was found in 70% and 80% of tumours, respectively and both were present in 54%. Cytoplasmic immunoreactivity correlated with tumour stage (p = 0.019). Survivin expression levels did not correlate with patient survival. In one specimen, cytoplasmic and focal nuclear immunostaining was observed in dysplastic bronchial squamous metaplasia. These results document that survivin overexpression is almost always present in early-stage NSCLC, suggesting that this protein may play a role in lung tumourigenesis. This ubiquitous expression makes survivin an appealing new target for novel therapies in lung cancer. In addition, this study also documents that survivin overexpression could be exploited for diagnostic purposes and that quantitative real-time RT-PCR can be a useful tool for evaluating survivin activation in NSCLC.

Original languageEnglish
Pages (from-to)620-626
Number of pages7
JournalJournal of Pathology
Volume200
Issue number5
DOIs
Publication statusPublished - Aug 1 2003

Fingerprint

Non-Small Cell Lung Carcinoma
Gene Expression
Neoplasms
Lung
Messenger RNA
Real-Time Polymerase Chain Reaction
Inhibitor of Apoptosis Proteins
Metaplasia
Mitosis
Squamous Cell Carcinoma
Lung Neoplasms
Cell Survival
Proteins
Immunohistochemistry
Carcinoma
Survival
Therapeutics

Keywords

  • Immunohistochemistry
  • Non-small cell lung carcinoma
  • Real-time RT-PCR
  • Survivin

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Falleni, M., Pellegrini, C., Marchetti, A., Oprandi, B., Buttitta, F., Barassi, F., ... Bosari, S. (2003). Survivin gene expression in early-stage non-small cell lung cancer. Journal of Pathology, 200(5), 620-626. https://doi.org/10.1002/path.1388

Survivin gene expression in early-stage non-small cell lung cancer. / Falleni, Monica; Pellegrini, Caterina; Marchetti, Antonio; Oprandi, Barbara; Buttitta, Fiamma; Barassi, Fabio; Santambrogio, Luigi; Coggi, Guido; Bosari, Silvano.

In: Journal of Pathology, Vol. 200, No. 5, 01.08.2003, p. 620-626.

Research output: Contribution to journalArticle

Falleni, M, Pellegrini, C, Marchetti, A, Oprandi, B, Buttitta, F, Barassi, F, Santambrogio, L, Coggi, G & Bosari, S 2003, 'Survivin gene expression in early-stage non-small cell lung cancer', Journal of Pathology, vol. 200, no. 5, pp. 620-626. https://doi.org/10.1002/path.1388
Falleni M, Pellegrini C, Marchetti A, Oprandi B, Buttitta F, Barassi F et al. Survivin gene expression in early-stage non-small cell lung cancer. Journal of Pathology. 2003 Aug 1;200(5):620-626. https://doi.org/10.1002/path.1388
Falleni, Monica ; Pellegrini, Caterina ; Marchetti, Antonio ; Oprandi, Barbara ; Buttitta, Fiamma ; Barassi, Fabio ; Santambrogio, Luigi ; Coggi, Guido ; Bosari, Silvano. / Survivin gene expression in early-stage non-small cell lung cancer. In: Journal of Pathology. 2003 ; Vol. 200, No. 5. pp. 620-626.
@article{9a3b53e99faa40c4880c0eb3b62f5233,
title = "Survivin gene expression in early-stage non-small cell lung cancer",
abstract = "Survivin is an inhibitor of apoptosis protein, overexpressed in most human malignancies and implicated in mitosis regulation and preservation of cell viability. In order to investigate the prevalence and clinical significance of survivin in early-stage non-small cell lung carcinoma (NSCLC), survivin mRNA levels and protein expression were evaluated, using quantitative real-time RT-PCR and immunohistochemistry, respectively, in a series of 83 patients with stage I (IA and IB) surgically resected NSCLC. Detectable survivin mRNA levels could be demonstrated in all non-neoplastic lung tissue samples and in the tumours analysed. Survivin mRNA levels were elevated in 80 carcinomas (96{\%}) compared to normal lung (p = 0.008). Among all tumours, survivin transcripts were present at a higher level in squamous cell carcinomas (p = 0.0022). Cytoplasmic and nuclear immunoreactivity was found in 70{\%} and 80{\%} of tumours, respectively and both were present in 54{\%}. Cytoplasmic immunoreactivity correlated with tumour stage (p = 0.019). Survivin expression levels did not correlate with patient survival. In one specimen, cytoplasmic and focal nuclear immunostaining was observed in dysplastic bronchial squamous metaplasia. These results document that survivin overexpression is almost always present in early-stage NSCLC, suggesting that this protein may play a role in lung tumourigenesis. This ubiquitous expression makes survivin an appealing new target for novel therapies in lung cancer. In addition, this study also documents that survivin overexpression could be exploited for diagnostic purposes and that quantitative real-time RT-PCR can be a useful tool for evaluating survivin activation in NSCLC.",
keywords = "Immunohistochemistry, Non-small cell lung carcinoma, Real-time RT-PCR, Survivin",
author = "Monica Falleni and Caterina Pellegrini and Antonio Marchetti and Barbara Oprandi and Fiamma Buttitta and Fabio Barassi and Luigi Santambrogio and Guido Coggi and Silvano Bosari",
year = "2003",
month = "8",
day = "1",
doi = "10.1002/path.1388",
language = "English",
volume = "200",
pages = "620--626",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Survivin gene expression in early-stage non-small cell lung cancer

AU - Falleni, Monica

AU - Pellegrini, Caterina

AU - Marchetti, Antonio

AU - Oprandi, Barbara

AU - Buttitta, Fiamma

AU - Barassi, Fabio

AU - Santambrogio, Luigi

AU - Coggi, Guido

AU - Bosari, Silvano

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Survivin is an inhibitor of apoptosis protein, overexpressed in most human malignancies and implicated in mitosis regulation and preservation of cell viability. In order to investigate the prevalence and clinical significance of survivin in early-stage non-small cell lung carcinoma (NSCLC), survivin mRNA levels and protein expression were evaluated, using quantitative real-time RT-PCR and immunohistochemistry, respectively, in a series of 83 patients with stage I (IA and IB) surgically resected NSCLC. Detectable survivin mRNA levels could be demonstrated in all non-neoplastic lung tissue samples and in the tumours analysed. Survivin mRNA levels were elevated in 80 carcinomas (96%) compared to normal lung (p = 0.008). Among all tumours, survivin transcripts were present at a higher level in squamous cell carcinomas (p = 0.0022). Cytoplasmic and nuclear immunoreactivity was found in 70% and 80% of tumours, respectively and both were present in 54%. Cytoplasmic immunoreactivity correlated with tumour stage (p = 0.019). Survivin expression levels did not correlate with patient survival. In one specimen, cytoplasmic and focal nuclear immunostaining was observed in dysplastic bronchial squamous metaplasia. These results document that survivin overexpression is almost always present in early-stage NSCLC, suggesting that this protein may play a role in lung tumourigenesis. This ubiquitous expression makes survivin an appealing new target for novel therapies in lung cancer. In addition, this study also documents that survivin overexpression could be exploited for diagnostic purposes and that quantitative real-time RT-PCR can be a useful tool for evaluating survivin activation in NSCLC.

AB - Survivin is an inhibitor of apoptosis protein, overexpressed in most human malignancies and implicated in mitosis regulation and preservation of cell viability. In order to investigate the prevalence and clinical significance of survivin in early-stage non-small cell lung carcinoma (NSCLC), survivin mRNA levels and protein expression were evaluated, using quantitative real-time RT-PCR and immunohistochemistry, respectively, in a series of 83 patients with stage I (IA and IB) surgically resected NSCLC. Detectable survivin mRNA levels could be demonstrated in all non-neoplastic lung tissue samples and in the tumours analysed. Survivin mRNA levels were elevated in 80 carcinomas (96%) compared to normal lung (p = 0.008). Among all tumours, survivin transcripts were present at a higher level in squamous cell carcinomas (p = 0.0022). Cytoplasmic and nuclear immunoreactivity was found in 70% and 80% of tumours, respectively and both were present in 54%. Cytoplasmic immunoreactivity correlated with tumour stage (p = 0.019). Survivin expression levels did not correlate with patient survival. In one specimen, cytoplasmic and focal nuclear immunostaining was observed in dysplastic bronchial squamous metaplasia. These results document that survivin overexpression is almost always present in early-stage NSCLC, suggesting that this protein may play a role in lung tumourigenesis. This ubiquitous expression makes survivin an appealing new target for novel therapies in lung cancer. In addition, this study also documents that survivin overexpression could be exploited for diagnostic purposes and that quantitative real-time RT-PCR can be a useful tool for evaluating survivin activation in NSCLC.

KW - Immunohistochemistry

KW - Non-small cell lung carcinoma

KW - Real-time RT-PCR

KW - Survivin

UR - http://www.scopus.com/inward/record.url?scp=0043025147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043025147&partnerID=8YFLogxK

U2 - 10.1002/path.1388

DO - 10.1002/path.1388

M3 - Article

VL - 200

SP - 620

EP - 626

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 5

ER -